ETOP IBCSG Partners Foundation

Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA)

CollaboratorPhase 3Recruiting2023220 people23 Aug 2022clinicaltrials.gov

NCT04595565

CollaboratorPhase 3Active, not recruiting20201,332 people20 Oct 2020clinicaltrials.gov

NCT03609047

CollaboratorPhase 2Active, not recruiting2019366 people1 Aug 2018clinicaltrials.gov

NCT02129699

Phase 3Terminated2015595 people2 May 2014clinicaltrials.gov

NCT01101438

CollaboratorPhase 3Completed20103,649 people12 Apr 2010clinicaltrials.gov

NCT00659373

Phase 3Completed200786 people16 Apr 2008clinicaltrials.gov

NCT00296010

Phase 3Terminated200577 people24 Feb 2006clinicaltrials.gov

NCT00002784

Phase 3Completed1996344 people29 Jul 2004clinicaltrials.gov

NCT00002529

Phase 3Completed1993452 people29 Jul 2004clinicaltrials.gov

NCT00074152

Phase 3Completed2002162 people11 Dec 2003clinicaltrials.gov

NCT00066807

Phase 3Terminated200329 people7 Aug 2003clinicaltrials.gov

NCT00066703

Phase 3Completed20032,672 people7 Aug 2003clinicaltrials.gov

NCT00066690

Phase 3Completed20033,066 people7 Aug 2003clinicaltrials.gov

NCT00004205

Phase 3Completed19988,028 people27 Jan 2003clinicaltrials.gov

NCT00002528

Phase 3Completed1993473 people27 Jan 2003clinicaltrials.gov